Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development
Pa-positive NCFB patients experienced a significant reduction in annualised…
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Presentation will provide additional analysis from the Phase IIa study of…
Infex Therapeutics written submission to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)
Below is the text that Infex Therapeutics submitted to the Presidential…
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Study met its primary objective demonstrating excellent safety and…
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading…
World AMR Awareness Week 2025
This World AMR Awareness Week, we're proud to be celebrating our collaboration…
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired…
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…